Institute for Advanced Diagnostics and Therapeutics Symposium

April 1, 2022

This presentation will be an ONLINE VIRTUAL LIVE broadcast on April 1, 2022, from 12:00 pm - 4:15 pm ET. While this activity is LIVE and can only be viewed during the time specified, the evaluation will be available online until April 29, 2022. Go to the Register tab above to learn how to participate for continuing education credit, watch the broadcast and download the slides.

The views and opinions expressed by this presenter in this lecture are their own, and do not represent the views of Sheppard Pratt.

Transformational change is happening in psychiatry. From the rapid expansion in the uses of neuromodulation, to the introduction of medications which may relieve depressive symptoms in hours or days rather than weeks or months, to the groundbreaking research into the use of psychedelic medication combined with psychotherapy—psychiatry is experiencing a quantum shift in how we regard psychiatric illness and what our capacity is to relieve the suffering in people with mood and anxiety disorders.  Sheppard Pratt is taking a leadership role in the development of these novel interventions by creating the Institute of Advanced Diagnostics and Therapeutics. 

We are excited to introduce the components of the Institute and feature the clinicians and researchers who are leading this effort.  This symposium will discuss the define the problem of difficult to treat depression and provide insight into the current clinical answers and the future answers that will come through our research.  Topics covered will include the evolution of Electroconvulsive Therapy into a more patient friendly intervention for acute, severe depression, the increasing footprint of Transcranial Magnetic Stimulation as a non-pharmacologic, somatic therapy for depression as well as for obsessive compulsive disorder and addictions, and finally look at the exciting developments in the use of psychedelic therapies for depression and PTSD being pioneered at the Sheppard Pratt Psychedelic Centre of Excellence. 

Target Audience

This activity is intended for physicians, nurses, psychologists, social workers, counselors and other mental health professionals. 

Learning Objectives

At the conclusion of this activity, attendees will be able to:

  1. Identify three factors to consider when evaluating a patient who presents with symptoms suggestive of difficult to treat depression.
  2. Describe how ECT has changed over time to improve the overall treatment experience.
  3. Describe the current and potential future indications for use of TMS in the psychiatric patient population.  
  4. Compare current modalities of psychiatric care with the emerging paradigm for psychedelic psychotherapy

 

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Category I credits for Social Workers
  • 4.00 CEU Hours for Psychologists
  • 4.00 MNA Contact Hours for Nurses
  • 4.00 Participation
Course opens: 
12/21/2021
Course expires: 
04/29/2022
Event starts: 
04/01/2022 - 12:00pm EDT
Event ends: 
04/01/2022 - 4:15pm EDT
Fee:
$0.00

Institute for Advanced Diagnostics and Therapeutics Symposium

This presentation will be an ONLINE LIVE broadcast on April 1, 2022, from 12:00 PM - 4:15 PM ET. While this activity is broadcast LIVE, the evaluation will be online until April 29, 2022. The link to attend the broadcast and download the slides will be emailed to registrants.

 

12:00 pm – 12:30 pm          Difficult to Treat Mood Disorders: An Overview

                          Scott Aaronson, MD          

                        Director, Institute for Diagnostics and Therapeutics              

                          Director, Clinical Research Program

12:30 pm – 1:15 pm          Electro-Convulsive Therapy: Making Treatment Better

Monica Rettenmier, MD    

Service Chief, Electroconvulsive Therapy         

                          Senior Psychiatrist, Child & Adolescent Services

1:15 pm – 2:00 pm              Transcranial Magnetic Stimulation: The Future is Now             

 Patricia Carlson, MD                    

                           Service Chief, TMS Programs

2:00 pm- 2:15pm              BREAK

2:15 pm – 3:15 pm              Psychedelics, MDMA and Ketamine: Forging a New Path to Well    

  Scott Aaronson, MD                 

3:15 pm – 4:15 pm              Expert Panel- Q & A Session

  Scott Aaronson, MD, Patricia Carlson, MD, Monica Rettenmier, MD    

4:15 pm              End of Broadcast

In the event an announced speaker is unable to present, Sheppard Pratt reserves the right to present an alternative speaker on a comparable subject.

There is no commercial support for this activity.

About the speakers

Scott Aaronson, MD, is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt in Baltimore, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr Aaronson specializes in treatment-resistant affective disorders. His work focuses on the development of various novel paradigms including neurostimulation and psychedelic assisted psychotherapy to treat severe mood disorders. He has been an international leader in the development of vagus nerve stimulation and transcranial magnetic stimulation. He is a member of the Board of Directors of the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School and completed a residency in psychiatry at McLean Hospital.  He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.

Monica Rettenmier, MD is board certified in both child/adolescent and adult psychiatry.  She is the service chief of the Electroconvulsive Therapy department at Sheppard Pratt.  Her areas of interest include primary mood disorders, including treatment resistant unipolar and bipolar depression, as well as anxiety disorders, in both adult and pediatric populations. Dr. Rettenmier is trained in the Neuromodulation areas of electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS).  She also works as a staff child/adolescent psychiatrist in the Telehealth Outpatient Services of Sheppard Pratt.  Before this role, she worked as a staff psychiatrist in the Child/Adolescent Partial Hospitalization Program of Sheppard Pratt, providing care to children and adolescents in an acute care setting.

Patricia Carlson, MD is a board-certified adult psychiatrist and is service chief of the TMS program for Sheppard Pratt.  Her areas of interest include mood disorders, including treatment resistant depression, as well as generalized anxiety and obsessive-compulsive disorder.  Dr. Carlson is on staff with the Department of Clinical Research at Sheppard Pratt, where she works with research protocols related to treatment resistant depression.  She is trained in multiple forms of Neurostimulation including transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and VNS protocols.  She is trained in transference focused psychotherapy (TFP), dialectical behavior therapy (DBT), and exposure response prevention therapy. She has taught courses in shame resilience and other topics related to common human sufferings such as loss and trauma. 

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she (or a partner or spouse) has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Scott T. Aaronson, MD, reports having the following relationships with financial interest: Compass Pathways- researcher, consultant; Neuronetics- researcher, consultant; LivaNova- researcher, consultant; Janssen- consultant; Sage Therapeutics- consultant; and Genomind- consultant. He will be discussing treatment utilizing Esketamine, TMS, and ECT as well as discussing off-label uses regarding research into psychedelics for multiple psychiatric indications.

Monica N. Rettenmier, MD, reports having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. She will be discussing ECT and its service options in this presentation.

Patricia Carlson MDreports that she has no relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months. She will not discuss any products, services, or off-label uses in this presentation.


Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Todd Peters, MD, Deepak Prabhakar, MD, Briana, Riemer, MD, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Bruce Boxer, PhD, MBA, MA, MSN, RN, NPD-BC, NEA-BC, MCHES, CPHQ, Stacey Garnett, RN, MSN, Heather Billings, RN, and Jennifer Tornabene.

Physician Statement: Sheppard Pratt is accredited by The Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity.  Sheppard Pratt designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Statement: Sheppard Pratt is an approved provider of continuing nursing education by Maryland Nurses Association. The Maryland Nurses Association is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CME activity. This activity provides 4.0 contact hours for nurses.

Psychologist Statement: Sheppard Pratt is authorized by the State Board of Examiners of Psychologists as a sponsor of continuing education. Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity.  Sheppard Pratt designates this educational activity for a maximum of 4.0 contact hours for Psychologists.

Social Worker Statement: Sheppard Pratt is authorized by the Board of Social Work Examiners of Maryland to offer continuing education for Social Workers.  Sheppard Pratt takes responsibility for the content, quality, and scientific integrity of this CE activity. This activity is approved for 4.0 contact hours in Category I credits for Social Workers.

 

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Category I credits for Social Workers
  • 4.00 CEU Hours for Psychologists
  • 4.00 MNA Contact Hours for Nurses
  • 4.00 Participation

Price

Fee:
$0.00
Please login or register to take this course.

Institute for Advanced Diagnostics and Therapeutics Symposium

This presentation will be an ONLINE LIVE broadcast on April 1, 2022, from 12:00 PM - 4:15 PM ET. While this activity is broadcast LIVE, the evaluation will be online until April 29, 2022. The link to attend the broadcast and download the slides will be emailed to registrants.

 

12:00 pm – 12:30 pm          Difficult to Treat Mood Disorders: An Overview

                          Scott Aaronson, MD          

                        Director, Institute for Diagnostics and Therapeutics              

                          Director, Clinical Research Program

12:30 pm – 1:15 pm          Electro-Convulsive Therapy: Making Treatment Better

Monica Rettenmier, MD    

Service Chief, Electroconvulsive Therapy         

                          Senior Psychiatrist, Child & Adolescent Services

1:15 pm – 2:00 pm              Transcranial Magnetic Stimulation: The Future is Now             

 Patricia Carlson, MD                    

                           Service Chief, TMS Programs

2:00 pm- 2:15pm              BREAK

2:15 pm – 3:15 pm              Psychedelics, MDMA and Ketamine: Forging a New Path to Well    

  Scott Aaronson, MD                 

3:15 pm – 4:15 pm              Expert Panel- Q & A Session

  Scott Aaronson, MD, Patricia Carlson, MD, Monica Rettenmier, MD    

4:15 pm              End of Broadcast

In the event an announced speaker is unable to present, Sheppard Pratt reserves the right to present an alternative speaker on a comparable subject.

Required Hardware/software

Optimal System Configuration

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

Hardware/Software Specifications

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.